Mebeverine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mebeverine
Accession Number
DB12554
Description

Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 429.557
Monoisotopic: 429.251523231
Chemical Formula
C25H35NO5
Synonyms
  • Mebeverina
  • Mebeverine
  • Mebeverinum
External IDs
  • BRN 2783282

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Mebeverine.
AclidiniumThe risk or severity of adverse effects can be increased when Mebeverine is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Mebeverine.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mebeverine.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Mebeverine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Mebeverine hydrochloride15VZ5AL4JN2753-45-9PLGQWYOULXPJRE-UHFFFAOYSA-N
International/Other Brands
Colofac / Duspatal / Duspatalin / Rudakol

Categories

ATC Codes
A03AA04 — Mebeverine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as p-methoxybenzoic acids and derivatives. These are benzoic acids in which the hydrogen atom at position 4 of the benzene ring is replaced by a methoxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
P-methoxybenzoic acids and derivatives
Alternative Parents
M-methoxybenzoic acids and derivatives / Amphetamines and derivatives / Benzoic acid esters / Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Aralkylamines
show 7 more
Substituents
Alkyl aryl ether / Amine / Amino acid or derivatives / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Benzoate ester / Benzoyl / Carboxylic acid derivative
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
7F80CC3NNV
CAS number
3625-06-7
InChI Key
VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
IUPAC Name
4-{ethyl[1-(4-methoxyphenyl)propan-2-yl]amino}butyl 3,4-dimethoxybenzoate
SMILES
CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1

References

General References
Not Available
PubChem Compound
4031
PubChem Substance
347828778
ChemSpider
3891
RxNav
29410
ChEBI
91514
ChEMBL
CHEMBL282121
Wikipedia
Mebeverine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCancer, Bladder / Incontinence / Incontinence, Daytime Urinary / Incontinence, Nighttime Urinary / Oncology / Orthotopic Neobladder1
4CompletedTreatmentIrritable Bowel Syndrome (IBS)1
3RecruitingTreatmentIrritable Bowel Syndrome (IBS)1
Not AvailableCompletedNot AvailablePost-cholecystectomy Gastrointestinal Spasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule, liquid filledOral200 mg
Tablet135 mg
Tablet, sugar coatedOral135 mg
CapsuleOral200 mg
Tablet, coatedOral135 MG
Capsule, extended releaseOral200 MG
Tablet, coatedOral135 mg/1
Tablet, sugar coatedOral
Tablet, coated100 mg
SyrupOral10 mg/ml
Capsule200 mg
Tablet
Tablet100 mg
Tablet, film coatedOral
Capsule, delayed releaseOral200 mg
Tablet, film coatedOral135 MG
TabletOral135 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0029 mg/mLALOGPS
logP4.87ALOGPS
logP4.89ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)10.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area57.23 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity123.54 m3·mol-1ChemAxon
Polarizability49.66 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0000900000-211570923a386119fb40
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001j-0700900000-99c57564f3fc24c545e0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006t-0900000000-c0682f422d00560d08ba
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0900000000-2e05532c5e033b444833
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-1900000000-932bf2e1c980e01c0e84
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ea-0900300000-a95ec1fe9eb9355e870d

Drug created on October 20, 2016 16:50 / Updated on August 14, 2020 15:41

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates